Cellectis S.a. (CLLS)

$2.24

-0.03

(-1.32%)▲

Market is closed - opens 7 PM, 09 Sep 2024

Performance

  • $2.16
    $2.27
    $2.24
    downward going graph

    3.57%

    Downside

    Day's Volatility :4.85%

    Upside

    1.32%

    downward going graph
  • $0.96
    $3.77
    $2.24
    downward going graph

    57.02%

    Downside

    52 Weeks Volatility :74.49%

    Upside

    40.64%

    downward going graph

Returns

PeriodCellectis S.a.Sector (Health Care)Index (Russel 2000)
3 Months
-12.84%
5.1%
0.0%
6 Months
-10.76%
4.9%
0.0%
1 Year
24.44%
16.6%
0.0%
3 Years
-85.06%
13.2%
-22.3%

Highlights

Market Capitalization
225.7M
Book Value
$1.49
Earnings Per Share (EPS)
-1.23
PEG Ratio
0.0
Wall Street Target Price
7.0
Profit Margin
0.0%
Operating Margin TTM
-181.11%
Return On Assets TTM
-17.3%
Return On Equity TTM
-64.37%
Revenue TTM
19.6M
Revenue Per Share TTM
0.28
Quarterly Revenue Growth YOY
374.90000000000003%
Gross Profit TTM
24.0M
EBITDA
-77.4M
Diluted Eps TTM
-1.23
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.79
EPS Estimate Next Year
-0.69
EPS Estimate Current Quarter
-0.3
EPS Estimate Next Quarter
-0.26

Analyst Recommendation

Buy
    85%Buy
    14%Hold
    0
    0%Sell
Based on 14 Wall street analysts offering stock ratings for Cellectis S.a.(by analysts ranked 0 to 5 stars)
Based on 14 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
12
12
12
Hold
2
2
2
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 212.5%

Current $2.24
Target $7.00

Company Financials

FY18Y/Y Change
Revenue
12.7M
↓ 49.46%
Net Income
-78.7M
↓ 20.81%
Net Profit Margin
-618.12%
↓ 223.61%
FY19Y/Y Change
Revenue
15.2M
↑ 19.32%
Net Income
-90.7M
↑ 15.24%
Net Profit Margin
-597.01%
↑ 21.11%
FY20Y/Y Change
Revenue
73.9M
↑ 386.83%
Net Income
-72.6M
↓ 19.98%
Net Profit Margin
-98.14%
↑ 498.87%
FY21Y/Y Change
Revenue
73.9M
↑ 0.0%
Net Income
-86.3M
↑ 18.89%
Net Profit Margin
-116.68%
↓ 18.54%
FY22Y/Y Change
Revenue
19.2M
↓ 74.08%
Net Income
-98.7M
↑ 14.38%
Net Profit Margin
-514.78%
↓ 398.1%
FY23Y/Y Change
Revenue
755.0K
↓ 96.06%
Net Income
-101.1M
↑ 2.4%
Net Profit Margin
-13.4K%
↓ 12870.52%
Q1 FY23Q/Q Change
Revenue
139.0K
↓ 99.13%
Net Income
-30.1M
↑ 17.01%
Net Profit Margin
-21.6K%
↓ 21475.57%
Q2 FY23Q/Q Change
Revenue
155.0K
↑ 11.51%
Net Income
-17.5M
↓ 41.87%
Net Profit Margin
-11.3K%
↑ 10357.26%
Q3 FY23Q/Q Change
Revenue
283.0K
↑ 82.58%
Net Income
-42.9M
↑ 145.18%
Net Profit Margin
-15.1K%
↓ 3866.87%
Q4 FY23Q/Q Change
Revenue
283.0K
↑ 0.0%
Net Income
-42.9M
↑ 0.0%
Net Profit Margin
-15.1K%
↑ 0.0%
Q1 FY24Q/Q Change
Revenue
4.5M
↑ 1500.0%
Net Income
5.6M
↓ 113.17%
Net Profit Margin
124.62%
↑ 15270.2%
Q2 FY24Q/Q Change
Revenue
8.1M
↑ 78.03%
Net Income
-25.3M
↓ 547.81%
Net Profit Margin
-313.48%
↓ 438.1%
FY18Y/Y Change
Total Assets
500.8M
↑ 50.46%
Total Liabilities
50.6M
↑ 7.64%
FY19Y/Y Change
Total Assets
467.5M
↓ 6.66%
Total Liabilities
112.0M
↑ 121.48%
FY20Y/Y Change
Total Assets
469.5M
↑ 0.43%
Total Liabilities
160.6M
↑ 43.42%
FY21Y/Y Change
Total Assets
382.1M
↓ 18.62%
Total Liabilities
145.6M
↓ 9.35%
FY22Y/Y Change
Total Assets
261.2M
↓ 31.63%
Total Liabilities
135.3M
↓ 7.09%
FY23Y/Y Change
Total Assets
334.3M
↑ 27.97%
Total Liabilities
249.6M
↑ 84.49%
Q1 FY23Q/Q Change
Total Assets
251.4M
↓ 3.75%
Total Liabilities
130.9M
↓ 3.22%
Q2 FY23Q/Q Change
Total Assets
209.7M
↓ 16.59%
Total Liabilities
133.6M
↑ 2.03%
Q3 FY23Q/Q Change
Total Assets
334.3M
↑ 59.4%
Total Liabilities
249.6M
↑ 86.84%
Q4 FY23Q/Q Change
Total Assets
334.3M
↑ 0.0%
Total Liabilities
249.6M
↑ 0.0%
Q1 FY24Q/Q Change
Total Assets
354.5M
↑ 6.04%
Total Liabilities
263.9M
↑ 5.74%
Q2 FY24Q/Q Change
Total Assets
407.1M
↑ 14.86%
Total Liabilities
258.5M
↓ 2.03%
FY18Y/Y Change
Operating Cash Flow
-68.1M
↑ 30.21%
Investing Cash Flow
35.6M
↑ 1896.8%
Financing Cash Flow
236.5M
↑ 473.1%
FY19Y/Y Change
Operating Cash Flow
-69.1M
↑ 1.47%
Investing Cash Flow
-35.9M
↓ 200.7%
Financing Cash Flow
-3.9M
↓ 101.63%
FY20Y/Y Change
Operating Cash Flow
-80.3M
↑ 16.08%
Investing Cash Flow
-54.3M
↑ 51.49%
Financing Cash Flow
27.3M
↓ 807.46%
FY21Y/Y Change
Operating Cash Flow
-104.6M
↑ 30.28%
Investing Cash Flow
7.3M
↓ 113.39%
Financing Cash Flow
47.5M
↑ 73.94%
FY22Y/Y Change
Operating Cash Flow
-87.4M
↓ 16.37%
Investing Cash Flow
-2.8M
↓ 137.93%
Financing Cash Flow
1.1M
↓ 97.59%
Q1 FY23Q/Q Change
Operating Cash Flow
-28.3M
↑ 2221.8%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
19.8M
↓ 492.3%
Q2 FY23Q/Q Change
Operating Cash Flow
-17.1M
↓ 39.65%
Investing Cash Flow
-1.8M
↑ 0.0%
Financing Cash Flow
1.7M
↓ 91.47%

Technicals Summary

Sell

Neutral

Buy

Cellectis S.a. is currently in a neutral trading position according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cellectis S.a.
Cellectis S.a.
8.74%
-10.76%
24.44%
-85.06%
-81.19%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
5.97%
16.25%
37.11%
69.18%
305.56%
Novo Nordisk A/s
Novo Nordisk A/s
9.99%
-3.52%
34.24%
158.74%
417.73%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
-5.15%
64.67%
22.72%
31.08%
198.44%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
0.45%
14.0%
36.06%
143.5%
167.72%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cellectis S.a.
Cellectis S.a.
NA
NA
0.0
-0.79
-0.64
-0.17
NA
1.49
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
29.93
29.93
1.54
45.05
0.17
0.08
NA
261.41
Novo Nordisk A/s
Novo Nordisk A/s
44.01
44.01
1.98
3.44
0.89
0.23
0.01
25.24
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.55
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
0.57
0.32
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cellectis S.a.
Cellectis S.a.
Buy
$225.7M
-81.19%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$124.7B
305.56%
29.93
32.04%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$585.3B
417.73%
44.01
34.84%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$32.3B
198.44%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$120.9B
167.72%
32.84
-4.74%

Insights on Cellectis S.a.

  • Increasing Revenue

    Revenue is up for the last 6 quarters, 139.0K → 8.06M (in $), with an average increase of 38.6% per quarter

  • Decreasing Net Profit

    Netprofit is down for the last 2 quarters, 5.64M → -25.27M (in $), with an average decrease of 547.8% per quarter

  • Vs REGN

    In the last 1 year, Regeneron Pharmaceuticals, Inc. has given 37.1% return, outperforming this stock by 12.7%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 69.2% return, outperforming this stock by 154.3%

Institutional Holdings

  • Long Focus Capital Management, LLC

    4.48%

  • Capital Research & Mgmt Co - Division 3

    1.85%

  • Credit Suisse First Boston (CSFB)

    1.44%

  • Baillie Gifford & Co Limited.

    0.71%

  • Principal Financial Group Inc

    0.44%

  • Macquarie Group Ltd

    0.23%

Company Information

cellectis is a clinical-stage biopharmaceutical company focused on developing a new generation of cancer immunotherapies based on gene-edited t-cells (ucart). by capitalizing on its 18 years of expertise in gene editing – built on its flagship talen® technology and pioneering electroporation system pulseagile – cellectis uses the power of the immune system to target and eradicate cancer cells. using its life-science-focused, pioneering genome engineering technologies, cellectis’ goal is to create innovative products in multiple fields and with various target markets. cellectis is listed on the nasdaq market (ticker: clls) and on the nyse alternext market (ticker: alcls). to find out more about us, visit our website: www.cellectis.com talking about gene editing? we do it. talen® is a registered trademark owned by the cellectis group.

Organization
Cellectis S.a.
Employees
216
CEO
Dr. Andre Choulika Ph.D.
Industry
Health Technology

Discover More

FAQs